Arvinas, Inc. (ARVN) News
Track canonical SquawkNews coverage tagged to ARVN, Arvinas, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. NASDAQ:ARVN (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, tod
EQUITY | Sep 29, 2026, 08:08 PM UTC
L
Arvinas, Inc. (ARVN) Doses First Patient in ARV-6723 Phase 1/2 Trial
Arvinas dosed the first patient in a Phase 1/2 trial of ARV-6723, an oral HPK1-targeting PROTAC, as monotherapy and with pembrolizumab in advanced solid tumors.Material DetailsContext by AI AnalystThis is an early-stage
NEWS | Sep 28, 2026, 11:08 AM UTC
L
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors —NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. NASDAQ:ARVN, a
REGULATION | Sep 28, 2026, 11:08 AM UTC
H
Arvinas Q2 2026 Earnings Call Transcript
Arvinas (NASDAQ: ARVN ) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcr
LIVE | Sep 25, 2026, 11:25 AM UTC
L
ARVN outlines clinical pipeline readouts across four programs
ARVN said key data readouts are expected for four programs over the next 15 months. It highlighted ARV-393 and ARV-102 nearing pivotal milestones, plus biomarker-driven progress for SBMA and HPK1.
EQUITY | Sep 08, 2026, 07:22 PM UTC
L
ARVN pipeline update: four programs advance; data due within 15 months
ARVN said four programs are advancing as it shifts to a robust clinical pipeline. ARV-393 and ARV-102 are progressing in hematology and neurodegeneration, while SBMA and HPK1 target rare disease and immuno-oncology; key
EQUITY | Sep 08, 2026, 06:43 PM UTC
L
Arvinas management to take part in upcoming investor fireside chats
Arvinas, Inc. said management will participate in fireside chats at upcoming investor conferences.
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
ARVN - Arvinas to Participate in Upcoming Investor Conferences
ARVN - Arvinas to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 08:01 PM UTC
L
Arvinas grants 45,696 RSUs under Nasdaq Rule 5635(c)(4)
Arvinas announced it granted 45,696 restricted stock units under Nasdaq Listing Rule 5635(c)(4), an inducement equity award.
EQUITY | Sep 01, 2026, 08:08 PM UTC
L
ARVN announces Nasdaq Rule 5635(c)(4) inducement grant
Arvinas announced an inducement grant under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 08:01 PM UTC
L
ARVN - Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ARVN - Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 04, 2026, 11:01 AM UTC